Complementary Antitumor Immunity Induced by Plasmid DNA Encoding Secreted and Cytoplasmic Human ErbB-2

Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer

1989 • 6,734 citations

Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts.

1998 • 1,013 citations

Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer.

1989 • 592 citations

Molecular mechanisms underlying ErbB2/HER2 action in breast cancer

2000 • 580 citations

Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines.

1995 • 542 citations

Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer.

1994 • 467 citations

Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide.

1995 • 446 citations

Elevated expression of activated forms of Neu/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer

1999 • 445 citations

Overexpression of ErbB2 in cancer and ErbB2-targeting strategies

2000 • 409 citations

B cells inhibit induction of T cell-dependent tumor immunity

1998 • 393 citations

DNA Vaccination Against Rat Her-2/Neu p185 More Effectively Inhibits Carcinogenesis Than Transplantable Carcinomas in Transgenic BALB/c Mice

2000 • 354 citations

High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer.

1997 • 347 citations

c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes

1991 • 335 citations

NH2-terminally truncated HER-2/neu protein: relationship with shedding of the extracellular domain and with prognostic factors in breast cancer.

1998 • 248 citations

The Multi-epitope Approach for Immunotherapy for Cancer: Identification of Several CTL Epitopes from Various Tumor-Associated Antigens Expressed on Solid Epithelial Tumors

1998 • 235 citations

Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes.

1998 • 227 citations

Immunization with a peptide epitope (p369-377) from HER-2/neu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2/neu+ tumors.

1998 • 220 citations

Clinical trials of Herceptin® (trastuzumab)

2001 • 216 citations

Mechanistic aspects of the opposing effects of monoclonal antibodies to the ERBB2 receptor on tumor growth.

1991 • 208 citations

The ErbB-2/HER2 oncogenic receptor of adenocarcinomas: from orphanhood to multiple stromal ligands

1998 • 196 citations

First-line, single-agent Herceptin® (trastuzumab) in metastatic breast cancer

2001 • 185 citations

Population-Based, Case-Control Study of HER2 Genetic Polymorphism and Breast Cancer Risk

2000 • 179 citations

Identification of New HER2/neu-Derived Peptide Epitopes That Can Elicit Specific CTL Against Autologous and Allogeneic Carcinomas and Melanomas

1999 • 176 citations

The c‐erbB‐2 proto‐oncogene in human pancreatic cancer

1990 • 172 citations

Peptides derived from a wild-type murine proto-oncogene c-erbB-2/HER2/neu can induce CTL and tumor suppression in syngeneic hosts.

1997 • 157 citations

The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors.

2001 • 157 citations

Biological rationale for HER2/neu (c-erbB2) as a target for monoclonal antibody therapy.

2000 • 147 citations

c-erbB-2 oncoprotein expression in primary human tumors

1990 • 142 citations

Defining promiscuous MHC class II helper T-cell epitopes for the HER2/neu tumor antigen.

2000 • 137 citations

A novel splice variant ofHER2 with increased transformation activity

1998 • 130 citations

Immunological Enhancement: A Study of Blocking Antibodies

1972 • 120 citations

A novel hydrophobized polysaccharide/oncoprotein complex vaccine induces in vitro and in vivo cellular and humoral immune responses against HER2-expressing murine sarcomas.

1998 • 110 citations

Protection against mammary tumor growth by vaccination with full-length, modified humanErbB-2 DNA

1999 • 110 citations

DNA vaccines encoding full-length or truncated Neu induce protective immunity against Neu-expressing mammary tumors.

1998 • 107 citations

Identification of Her-2/Neu CTL epitopes using double transgenic mice expressing HLA-A2.1 and human CD.8

1997 • 107 citations

An evaluation of immunoreactivity for c-erbB-2 protein as a marker of poor short-term prognosis in breast cancer

1989 • 102 citations

Identification of HER2/neu-derived peptide epitopes recognized by gastric cancer-specific cytotoxic T lymphocytes

1998 • 94 citations

DNA vaccination with full-length or truncated Neu induces protective immunity against the development of spontaneous mammary tumors in HER-2/neu transgenic mice

2000 • 70 citations

FACS Quantitation of Leucine Aminopeptidase and Acid Phosphatase on Tumor-Associated Macrophages From Metastatic and Nonmetastatic Mouse Mammary Tumors

1985 • 69 citations

HER-2/neu is expressed in human renal cell carcinoma at heterogeneous levels independently of tumor grading and staging and can be recognized by HLA-A2.1-restricted cytotoxic T lymphocytes

2000 • 60 citations

Targeting HER-2/neu for active-specific immunotherapy in a mouse model of spontaneous breast cancer

1999 • 54 citations

A novel human HER2-derived peptide homologous to the mouse Kd-restricted tumor rejection antigen can induce HLA-A24-restricted cytotoxic T lymphocytes in ovarian cancer patients and healthy individuals

2000 • 49 citations

Proliferative and cytokine responses to class II HER-2/neu-associated peptides in breast cancer patients.

1998 • 48 citations

Combined measurement of the c-erbb-2 protein in breast carcinoma tissues and sera is useful as a sensitive tumor marker for monitoring tumor relapse

2000 • 46 citations

A HER2/NEU-derived peptide, a Kd-restricted murine tumor rejection antigen, induces HER2-specific HLA-A2402-restricted CD8+ cytotoxic T lymphocytes

2000 • 43 citations

c-erb B2 amplification and overexpression in human tumors

1991 • 43 citations

Mechanisms of escape from CD8+ T-cell clones specific for the HER-2/NEU proto-oncogene expressed in ovarian carcinomas: Related and unrelated to decreased MHC class 1 expression

1997 • 36 citations

Identification of naturally processed human ovarian peptides recognized by tumor-associated CD8+ cytotoxic T lymphocytes.

1997 • 31 citations

ErbB2 Immune Response in Breast Cancer Patients with Soluble Receptor Ectodomain

2000 • 28 citations

A Long-Term Memory Obtained by Genetic Immunization Results in Full Protection from a Mammary Adenocarcinoma Expressing an EBV Gene

1999 • 21 citations

Her2 and Trastuzumab in Breast Cancer

2001 • 19 citations

Detection of p105 (c-erbB-2, HER2/neu) serum levels by a new ELISA in patients with ovarian carcinoma.

1998 • 13 citations

Clinical development of trastuzumab in Breast Cancer

2001 • 4 citations